Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 10, 2015, Pages 1770-1775

  Yeshurun, Moshe ^a,b   Shpilberg, Ofer ^a,b   Herscovici, Corina ^a,b   Shargian, Liat ^a,b   Dreyer, Juliet ^a   Peck, Anat ^a   Israeli, Moshe ^a   Levy Assaraf, Maly ^b   Gruenewald, Tsipora ^a   Mechoulam, Raphael ^c   Raanani, Pia ^a,b   Ram, Ron ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Allogeneic hematopoietic cell transplantation; Cannabidiol; Cannabis sativa; Graft versus host disease; Prophylaxis

Indexed keywords

BUSULFAN; CANNABIDIOL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; MELPHALAN; METHOTREXATE; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASIA; ARTICLE; CANDIDEMIA; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HLA SYSTEM; HUMAN; INCIDENCE; LIVER VENOOCCLUSIVE DISEASE; MALE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; PHASE 2 CLINICAL TRIAL; SEPSIS; UNRELATED DONORS; ADVERSE EFFECTS; ALLOGRAFT; CLINICAL TRIAL; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFECTION; KAPLAN MEIER METHOD; MIDDLE AGED; PROSPECTIVE STUDY; YOUNG ADULT;

ADULT; AGED; ALLOGRAFTS; ANTI-INFLAMMATORY AGENTS; CANNABIDIOL; CYCLOSPORINE; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFECTION; KAPLAN-MEIER ESTIMATE; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84941315324     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.05.018     Document Type: Article

References (44)

1. Weisdorf D. GVHD-the nuts and bolts. Hematol Am Soc Hematol Educ Progr 2007, 2007:62-67.
2. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
3. Arora M., Klein J.P., Weisdorf D.J., et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood 2011, 117:6714-6720.
4. Jagasia M., Arora M., Flowers M.E., et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012, 119:296-307.
5. Kurosawa S., Yamaguchi T., Miyawaki S., et al. A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission. Blood 2011, 117:2113-2120.
6. Pacifici R., Zuccaro P., Pichini S., et al. Modulation of the immune system in cannabis users. JAMA 2003, 289:1929-1931.
7. Naftali T., Bar-Lev Schleider L., Dotan I., et al. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled trial. Clin Gastroenterol 2013, 11:1276-1280.
8. Brenneisen R. Chemistry and analysis of phytocannabinoids and other cannabis constituents. Marijuana and the cannabinoids 2007, 17-51. Human Press, Totowa, NJ. M. Elsohly (Ed.).
9. Pandey R., Hegde V.L., Nagarkatti M., Nagarkatti P.S. Targeting cannabinoid receptors as a novel approach in the treatment of graft versus host disease: evidence from an experimental murine model. J Pharmacol Exp Ther 2011, 338:819-828.
10. Cunha J.M., Carlini E.A., Pereira A.E., et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980, 21:175-185.
11. Consroe P., Laguna J., Allender J., et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 1991, 40:701-708.
12. Crippa J.A., Derenusson G.N., Ferrari T.B., et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 2011, 25:121-130.
13. Leweke F.M., Koethe D., Pahlisch F., et al. Antipsychotic effects of cannabidiol. Eur Psychiatry 2009, 24:S207.
14. Bergamaschi M.M., Queiroz R.H., Chagas M.H., et al. Cannabidiol reduces the anxiety induced by simulated public speaking in speaking treatment-naïve social phobia patients. Neuropsychopharmacology 2011, 36:1219-1226.
15. Hallak J.E., Machado-de-Sousa J.P., Crippa J.A., et al. Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). Rev Bras Psiquiatr 2010, 32:56-61.
16. Zuardi A.W., Hallak J.E., Dursun S.M., et al. Cannabidiol monotherapy for treatment resistant schizophrenia. J Psychopharmacol 2006, 20:683-686.
17. Zuardi A.W., Crippa J., Dursun S.M., et al. Cannabidiol was ineffective for manic episode of bipolar affective disorder. J Psychopharmacol 2010, 24:135-137.
18. Kozela E., Lev N., Kaushansky N., et al. Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorated multiple sclerosis-like disease in C57BL/6 mice. Br J Pharmacol 2011, 163:1507-1519.
19. Malfait A.M., Gallily R., Sumariwalla P.F., et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 2000, 97:9561-9566.
20. Borrelli F., Aviello G., Romano B., et al. Cannabidiol, a safe and non-psychotropic ingredient of marijuana plant Cannabis sativa, is protective in a murine model of colitis. J Mol Med 2009, 87:1111-1121.
21. Schicho R., Storr M. Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice. Pharmacology 2012, 89:149-155.
22. De Filippis D., Esposito G., Cirillo C., et al. Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. Plos One 2011, 6:1-8.
23. Weiss L., Zeira M., Reich S., et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 2006, 39:143-151.
24. Mechoulam R., Peters M., Murillo-Rodriguez E., Hanus L.O. Cannabidiol-recent advances. Chem Biodivers 2007, 4:1678-1692.
25. Basu S., Dittel B.N. Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol Res 2011, 51:26-38.
26. Adhikary S., Kocieda V.P., Yen J.H., et al. Signaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression. Blood 2012, 120:3741-3749.
27. Shimoni A., Hardan I., Shem-Tov N., et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006, 20:322-328.
28. Ram R., Yeshurun M., Farbman L., et al. Elevation of CRP precedes clinical suspicion of bloodstream infections in patients undergoing hematopoietic cell transplantation. J Infect 2013, 67:194-198.
29. Pzepiorka D., Weisdorf D., Martin P., et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
30. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic-graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
31. Blume K.G., Forman S.J., Appelbaum F.R., et al. Documentation of engraftment and characterization of chimerism following hematopoietic cell transplantation. Thomas hematopoietic cell transplantation 2004, 234-243. Blackwell, Oxford, UK. K.G. Blume, S.J. Forman, F.R. Appelbaum (Eds.).
32. Krisst D., Israeli M., Narinski R., et al. Hematopoietic chimerism monitoring based on STRs: quantitative platform performance on sequential samples. J Biomol Tech 2005, 16:380-391.
33. Cancer Therapy Evaluation Program. NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Published May 28, 2009. http://www.ctep.cancer.gov.
34. Armand P., Kim H.T., Logan B.R., et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood 2014, 123:3664-3671.
35. Brunet S., Labopin M., Esteve J., et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol 2012, 30:735-741.
36. Saber W., Opie S., Rizzo J.D., et al. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myeloid leukemia. Blood 2012, 119:3908-3916.
37. Storb R., Gyurkocza B., Storer B.E., et al. Graft-versus-host disease and graft-versus-tumor-effects after allogeneic hematopoietic cell transplantation. J Clin Oncol 2013, 31:1530-1538.
38. Reshef R., Luger S.M., Hexner E.O., et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host-disease. N Engl J Med 2012, 367:135-145.
39. Koreth J., Stevenson K.E., Kim H.T., et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol 2012, 30:3202-3208.
40. Choi S.W., Braun T., Chang L., et al. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haematopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol 2014, 15:87-95.
41. Gallily R., Even-Chen T., Katzavian G., et al. γ-Irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk Lymph 2003, 44:1767-1773.
42. phox and Nox4 expression. Mol Pharm 2006, 70:897-908.
43. Massi P., Solinas M., Cinquina V., Parolaro D. Cannabidiol as potential anticancer drug. Br J Clin Pharmacol 2012, 75:303-312.
44. Champlin R.E., Perez W.S., Passweg J.R., et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 2007, 109:4582-4585.